Breast Cancer Risk in Users of Hormonal Contraception
DOI:
https://doi.org/10.12775/QS.2026.50.68099Keywords
hormonal contraception, combined oral contraception (COCs), breast cancer, cancer risk, BRCA1/BRCA2 mutations, Breast cancer mortalityAbstract
Combined oral contraceptives (COCs) are a widely used method of birth control among women. They have a low Pearl Index, confirming high efficacy. Their mechanism of action relies on suppression of ovulation. This is achieved through the influence of estrogenic and progestogenic components on the release of follicle-stimulating hormone and luteinizing hormone from the pituitary gland. COCs also inhibit fertilization by altering cervical mucus composition and prevent blastocyst implantation.
The mechanism of action of COCs allows their use for non-contraceptive purposes. For example, they reduce the risk of ovarian and endometrial cancer. They also limit menstrual bleeding and alleviate acne, migraine headaches, and dysphoric symptoms. Conversely, adverse effects of COCs include an increased risk of cervical cancer. Their impact on breast cancer remains inconclusive.
Clinical studies have demonstrated that the overall incidence of breast cancer among women using COCs is comparable to that among women who have never used them. However, during COC use and shortly after discontinuation, the risk of developing breast cancer is elevated, whereas it decreases five years after cessation. Among women with BRCA1 or BRCA2 mutations, the impact of COCs remains uncertain, with some studies reporting increased risk and others suggesting a reduction.
Breast cancer is the most frequently diagnosed malignancy among women and the second leading cause of cancer-related death. Prognosis is often dependent on the stage at diagnosis. Mortality risk due to breast cancer is higher among women using COCs, whereas it does not significantly change with the use of progestin-only oral contraceptives.
Some patients discontinue oral contraception due to concerns about adverse effects and a potential increase in breast cancer risk. The aim of this study was to present the mechanisms of COC action within breast tissue and their influence on the risk of breast cancer.
References
1. Sitruk-Ware R, Nath A, Mishell DR Jr. Contraception technology: past, present and future. https://doi.org/10.1016/j.contraception.2012.08.002
2. Creinin MD, Westhoff CL, Bouchard C, Chen MJ, Jensen JT, Kaunitz AM, et al. Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results. https://doi.org/10.1016/j.contraception.2021.05.002
3. Medard M L, Ostrowska L. Combined oral contraception and the risk of reproductive organs cancer in women. Ginekol Pol. 2007;78(8):637–41, PMID: 18050614.
4. Brown EJ, Deshmukh P, Antell K. Contraception update: Oral contraception. FP Essent. 2017;462:11–9. PMID: 29172411
5. Fraser IS. Non-contraceptive health benefits of intrauterine hormonal systems. 2010;82(5):396–403, https://doi.org/10.1016/j.contraception.2010.05.005
6. Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ Oral Contraception Study. Am J Obstet Gynecol. 2017;216(6):580.e1-580.e9. https://doi.org/10.1016/j.ajog.2017.02.002
7. Cieśla S, Wichtowski M, Poźniak-Balicka R, Murawa D. Anatomia chirurgiczna gruczołu piersiowego. Budowa ogólna, embriogeneza, histologia, kompleks brodawkowo-otoczkowy, powięzie tkanki gruczołowej i ściany klatki piersiowej. Część pierwsza. Nowotwory. 2020;70(5):211–9. https://doi.org/10.5603/NJO.2020.0042
8. Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal
contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol. 1999;181(5 Pt 1):1263–9
https://doi.org/10.1016/s0002-9378(99)70120-1
9. Deptała, A., Smoter, M., & Stec, R. (2019). Onkologia: podręcznik dla studentów
medycyny. Pomoc dydaktyczna dla lekarzy specjalizujących się w onkologii (I, p.466). AsteriaMed.
10. Marcin Makowski, Ireneusz Połać, Tomasz Pertyński. Oestrogens and breast cancer. Przegląd Menopauzalny 2007; 3: 150–154
11. Hubert Wolski, Selected aspects of oral contraception side effects; Ginekol Pol. 2014, 85, 944-949 https://doi.org/10.17772/gp/1887
12. Mariusz Bidziński, Anna Dańska-Bidzińska; Hormonal therapy after endometrial and breast cancer treatment; Przegląd Menopauzalny 2005; 4: 73–76
13. Bogusława Pietrzak, Ewelina Wlaźlak, Ewa Zwierzyńska; Long-term use of estrogens: benefit or risk. Postepy Hig Med Dosw, 2015; 69: 285-293 https://doi.org/10.5604/17322693.1142582
14. Huang J-C, Duan C-C, Jin S, Sheng C-B, Wang Y-S, Yue Z-P, et al. HB-EGF induces mitochondrial dysfunction via estrogen hypersecretion in granulosa cells dependent on cAMP-PKA-JNK/ERK-Ca2+-FOXO1 pathway. Int J Biol Sci. 2022;18(5):2047–59. https://doi.org/10.7150/ijbs.69343
15. Kamani M, Akgor U, Gültekin M. Review of the literature on combined oral contraceptives and cancer. Ecancermedicalscience. 2022;16:1416. https://doi.org/10.3332/ecancer.2022.1416
16. Hunter DJ, Colditz GA, Hankinson SE, Malspeis S, Spiegelman D, Chen W, et al.
Oral contraceptive use and breast cancer: a prospective study of young women. Cancer Epidemiol Biomarkers Prev. 2010;19(10):2496–502. https://doi.org/10.1158/1055-9965.EPI-10-0747
17. Marchbanks PA, Curtis KM, Mandel MG, Wilson HG, Jeng G, Folger SG, et al. Oral contraceptive formulation and risk of breast cancer. Contraception. 2012;85(4):342–50. https://doi.org/10.1016/j.contraception.2011.08.007
18. Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard Ø.
Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med. 2017;377(23):2228–39. https://doi.org/10.1056/nejmoa1700732
19. Park J, Huang D, Chang YJ, Lim MC, Myung S-K. Oral contraceptives and risk of breast cancer and ovarian cancer in women with a BRCA1 or BRCA2 mutation: a meta-analysis of observational studies. Carcinogenesis. 2022;43(3):231–42. https://doi.org/10.1093/carcin/bgab107
20. van Bommel MHD, IntHout J, Veldmate G, Kets CM, de Hullu JA, van Altena AM, et al. Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis. Hum Reprod Update. 2023;29(2):197–217. https://doi.org/10.1093/humupd/dmac038
21. Milne RL, Knight JA, John EM, Dite GS, Balbuena R, Ziogas A, et al. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev. 2005;14(2):350–6. https://doi.org/10.1158/1055-9965.epi-04-0376
22. Sulfiana S, Prihantono P, Usman AN, Ahmad M, Aryadi Arsyad M, Mumang AA.
Contraceptive use with breast cancer incidence in Indonesia. Breast Dis. 2024;43(1):127–34 https://doi.org/10.3233/bd-249007
23. Brynhildsen J. Combined hormonal contraceptives: prescribing patterns, compliance,
and benefits versus risks. Ther Adv Drug Saf [Internet]. 2014;5(5):201–13. https://doi.org/10.1177/2042098614548857
24. Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast
cancer-epidemiology, risk factors, classification, prognostic markers, and current
treatment strategies-an updated review. Cancers (Basel). 2021;13(17):4287. PMID: 34503097
25. Jakowczyk CM. Rak piersi wykrywany coraz częściej u kobiet przed 50. rokiem życia. Czas na zmiany w badaniach przesiewowych. Onkonet.pl. [cited 2025Aug 29]. https://www.onkonet.pl/n_n_rakpiersi_konieczne_zmiany_w_badaniach_przesiewowych.php
26. Christin-Maitre S. La contraception à travers le monde. Med Sci (Paris). 2022;38(5):457–63. https://doi.org/10.1051/medsci/2022058
27. Cooper DB, Patel P. Oral contraceptive pills. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. https://www.ncbi.nlm.nih.gov/books/NBK430882/
28. Trivers KF, Gammon MD, Abrahamson PE, Lund MJ, Flagg EW, Moorman PG, et al. Oral contraceptives and survival in breast cancer patients aged 20 to 54 years. Cancer Epidemiol Biomarkers Prev. 2007;16(9):1822–7. https://doi.org/10.1158/1055-9965.epi-07-0053
29. Samson ME, Adams SA, Mulatya CM, Zhang J, Bennett CL, Hebert J, et al. Types of oral contraceptives and breast cancer survival among women enrolled in Medicaid: A competing-risk model. Maturitas 2017;95:42–9. https://doi.org/10.1016/j.maturitas.2016.10.014
30. Barriga P, Vanhauwaert P, Porcile A. Hormonal contraception and risk of breast
cancer: a critical look. Gynecol Endocrinol 2019;35(6):460–2. https://doi.org/10.1080/09513590.2019.1576610
31. Wingo PA, Austin H, Marchbanks PA, Whiteman MK, Hsia J, Mandel MG, et al. Oral contraceptives and the risk of death from breast cancer. Obstet Gynecol. 2007;110(4):793–800 https://doi.org/10.1097/01.aog.0000284446.22251.6e
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Magdalena Grabińska, Aleksandra Buda, Paulina Halik, Justyna Jusiak, Tomasz Pietrucha, Mikołaj Gołdyn, Karolina Kubala, Adam Dudek, Daniel Zieliński, Małgorzata Sędek
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 11
Number of citations: 0
